Massive Bio taps Intralink to push into South Korea

Massive Bio has hired Intralink to help expand its oncology platform in South Korea and build partnerships with hospitals, labs and doctors. The move targets a market the company sees as strategically important to its broader Asia plan and its effort to match more cancer patients with clinical trials.

Why it matters: - Massive Bio is trying to gain a foothold in South Korea’s oncology market, where strong healthcare infrastructure and clinical research activity could help accelerate patient-trial matching. - The push could expand access to clinical trials for cancer patients in South Korea while giving pharmaceutical companies a larger pool of eligible participants.

What happened: - Massive Bio appointed international business development consultancy Intralink to support its expansion into South Korea. - Intralink’s Seoul team will engage hospitals, diagnostic laboratories and oncologists to build interest in Massive Bio’s platform. - The companies will also work together on industry outreach, including the 2026 AACR-KCA Joint Conference on Precision Medicine in Cancer in November.

The details: - Massive Bio runs an AI-powered platform that connects cancer patients with suitable clinical trials. - The company has matched 200,000 patients with 19,000 clinical trials across 17 markets. - Intralink operates from 27 locations worldwide, including Seoul, Silicon Valley, Boston, London, Paris, Düsseldorf, Poznań, Tokyo, Shanghai, Taipei, Bangkok and New Delhi. - Intralink will look for partnerships that strengthen Massive Bio’s ability to connect South Korean patients with appropriate trials and help drugmakers recruit patients. - Massive Bio CEO Selin Kurnaz said South Korea is important to the company’s broader Asian expansion because of its oncology ecosystem, advanced healthcare infrastructure and clinical research landscape. - Kurnaz also said Intralink’s Korea expertise and network will help Massive Bio understand the market, build partnerships and expand access to its platform. - Massive Bio describes itself as an agentic AI and real-world data company focused on oncology drug development, commercialization and precision medicine access. - The company says its RNex platform uses patient-consented multimodal data and clinical intelligence to identify patients, support trial enrollment and generate real-world evidence. - Massive Bio says it serves pharmaceutical and biotechnology companies, CROs, providers and researchers. - The company says it operates in 17 countries and is an OpenAI Select Partner, recipient of the DiMe Seal, founding member of CancerX and participant in the White House Cancer Moonshot initiative. - More information is available on Massive Bio’s website.

Between the lines: - The South Korea move suggests Massive Bio is shifting from broad international presence to deeper market-specific partnerships in one of Asia’s most advanced oncology environments. - Using Intralink gives Massive Bio a local business development team with established market-entry experience instead of building that network from scratch.

What's next: - Massive Bio and Intralink are expected to continue meeting Korean hospitals, labs and oncologists to identify collaboration opportunities. - The November cancer precision medicine conference is likely to be an early test of partner interest and market response. - Success in South Korea could give Massive Bio a template for further expansion across Asia.